{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:40:13Z","timestamp":1775652013602,"version":"3.50.1"},"reference-count":68,"publisher":"Becaris Publishing Limited","issue":"18","funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To determine the economic burden associated with anticholinergic medication use in adults with overactive bladder (OAB) in the USA.\n            <jats:bold>Methods:<\/jats:bold>\n            A systematic literature review was conducted to identify articles assessing healthcare resource utilization (HCRU) and costs associated with anticholinergic use in adults with OAB.\n            <jats:bold>Results:<\/jats:bold>\n            From the 34 articles identified, increased anticholinergic burden, switching anticholinergic treatments\u00a0and potentially inappropriate anticholinergic use were associated with increased HCRU and\/or costs. However, studies comparing patients with OAB receiving anticholinergics to individuals with untreated OAB or without OAB reported a mix of increases and decreases in HCRU and costs.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Additional controlled studies assessing the economic impact of anticholinergics in OAB are needed and may enable optimization of economic and potentially patient outcomes.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0160","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T13:23:17Z","timestamp":1668086597000},"page":"1375-1394","source":"Crossref","is-referenced-by-count":10,"title":["Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-2028","authenticated-orcid":false,"given":"Corinne","family":"Duperrouzel","sequence":"first","affiliation":[{"name":"EVERSANA, Burlington, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coby","family":"Martin","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Mendell","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Bourque","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Carrera","sequence":"additional","affiliation":[{"name":"Urovant Sciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-3038","authenticated-orcid":false,"given":"Alicia","family":"Mack","sequence":"additional","affiliation":[{"name":"Urovant Sciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Nesheim","sequence":"additional","affiliation":[{"name":"Urovant Sciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"crossref","unstructured":"Gormley EA Lightner DJ Burgio KL Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. American Urological Association MD USA (2019).","DOI":"10.1097\/JU.0000000000000309"},{"issue":"5","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne KS","year":"2011","unstructured":"Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5), 1081\u20131087 (2011).","journal-title":"Urology"},{"issue":"1","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359105314522084","article-title":"The psychological impact of overactive bladder: a systematic review","volume":"21","author":"Kinsey D","year":"2016","unstructured":"Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J. Health Psychol. 21(1), 69\u201381 (2016).","journal-title":"J. Health Psychol."},{"issue":"1","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom I","year":"2012","unstructured":"Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80(1), 90\u201396 (2012).","journal-title":"Urology"},{"issue":"11","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","article-title":"The association between overactive bladder and falls and fractures: a systematic review","volume":"35","author":"Szabo SM","year":"2018","unstructured":"Szabo SM, Gooch KL, Walker DR, Johnston KM, Wagg AS. The association between overactive bladder and falls and fractures: a systematic review. Adv. Ther. 35(11), 1831\u20131841 (2018).","journal-title":"Adv. Ther."},{"issue":"4","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/nau.23477","article-title":"The economic burden of overactive bladder in the United States: a systematic literature review","volume":"37","author":"Powell LC","year":"2018","unstructured":"Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol. Urodyn. 37(4), 1241\u20131249 (2018).","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/nau.23513","article-title":"The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States","volume":"37","author":"Durden E","year":"2018","unstructured":"Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States. Neurourol. Urodyn. 37(5), 1641\u20131649 (2018).","journal-title":"Neurourol. Urodyn."},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","article-title":"Real-world patterns of care for the overactive bladder syndrome in the United States","volume":"87","author":"Goldman HB","year":"2016","unstructured":"Goldman HB, Anger JT, Esinduy CB Real-world patterns of care for the overactive bladder syndrome in the United States. Urology 87, 64\u201369 (2016).","journal-title":"Urology"},{"issue":"2","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MLR.0000000000000858","article-title":"Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015","volume":"56","author":"Kinlaw AC","year":"2018","unstructured":"Kinlaw AC, Jonsson Funk M, Conover MM, Pate V, Markland AD, Wu JM. Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015. Med. Care 56(2), 162\u2013170 (2018).","journal-title":"Med. Care"},{"issue":"2","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/SPV.0000000000000744","article-title":"National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder","volume":"27","author":"Linder BJ","year":"2021","unstructured":"Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med. Reconstr. Surg. 27(2), e261\u2013e266 (2021).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"4","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman K","year":"2014","unstructured":"Maman K, Aballea S, Nazir J Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur. Urol. 65(4), 755\u2013765 (2014).","journal-title":"Eur. Urol."},{"issue":"12","key":"e_1_3_5_13_2","first-page":"CD003193","article-title":"Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults","volume":"12","author":"Rai BP","year":"2012","unstructured":"Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 12(12), CD003193 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland CAC","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Int. Med. 179(8), 1084\u20131093 (2019).","journal-title":"JAMA Int. Med."},{"issue":"3","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray SL","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Int. Med. 175(3), 401\u2013407 (2015).","journal-title":"JAMA Int. Med."},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson K","year":"2018","unstructured":"Richardson K, Fox C, Maidment I Anticholinergic drugs and risk of dementia: case-control study. BMJ 361, k1315 (2018).","journal-title":"BMJ"},{"issue":"6","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher SL","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 73(6), 721\u2013732 (2016).","journal-title":"JAMA Neurol."},{"issue":"1","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12877-019-1401-y","article-title":"Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study","volume":"19","author":"Wang YC","year":"2019","unstructured":"Wang YC, Chen YL, Huang CC Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatr. 19(1), 380 (2019).","journal-title":"BMC Geriatr."},{"issue":"2","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1370\/afm.2501","article-title":"Assessing risks of polypharmacy involving medications with anticholinergic properties","volume":"18","author":"Hanlon P","year":"2020","unstructured":"Hanlon P, Quinn TJ, Gallacher KI Assessing risks of polypharmacy involving medications with anticholinergic properties. Ann. Fam. Med. 18(2), 148\u2013155 (2020).","journal-title":"Ann. Fam. Med."},{"issue":"1","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis","volume":"40","author":"Dmochowski RR","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol. Urodyn. 40(1), 28\u201337 (2021).","journal-title":"Neurourol. Urodyn."},{"issue":"4","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 67(4), 674\u2013694 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"e_1_3_5_22_2","article-title":"Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis","volume":"71","author":"Sussman D","year":"2017","unstructured":"Sussman D, Yehoshua A, Kowalski J Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int. J. Clin. Pract. 71(3\u20134), (2017).","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner JS","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 105(9), 1276\u20131282 (2010).","journal-title":"BJU Int."},{"issue":"2","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/nau.22943","article-title":"Persistence with mirabegron therapy for overactive bladder: a real life experience","volume":"36","author":"Pindoria N","year":"2017","unstructured":"Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol. Urodyn. 36(2), 404\u2013408 (2017).","journal-title":"Neurourol. Urodyn."},{"key":"e_1_3_5_25_2","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0.","author":"Higgins JPT","year":"2011","unstructured":"Higgins JPT, Thomas J, Chandler Jet al. (Eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. John Wiley & Sons, Chichester, UK (2011)."},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"issue":"9760","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(10)60903-8","article-title":"An international registry of systematic-review protocols","volume":"377","author":"Booth A","year":"2011","unstructured":"Booth A, Clarke M, Ghersi D, Moher D, Petticrew M, Stewart L. An international registry of systematic-review protocols. Lancet 377(9760), 108\u2013109 (2011).","journal-title":"Lancet"},{"issue":"6","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs SH","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community Health 52(6), 377\u2013384 (1998).","journal-title":"J. Epidemiol. Community Health"},{"issue":"7052","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond MF","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313(7052), 275\u2013283 (1996).","journal-title":"BMJ"},{"issue":"2","key":"e_1_3_5_30_2","first-page":"88","article-title":"A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder","volume":"13","author":"Arikian SR","year":"2000","unstructured":"Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag. Care Interface 13(2), 88\u201394 (2000).","journal-title":"Manag. Care Interface"},{"issue":"1","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3111\/13696998.2012.732635","article-title":"Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder","volume":"15","author":"Armstrong EP","year":"2012","unstructured":"Armstrong EP, Malone DC, Bui CN. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. J. Med. Econ. 15(Suppl. 1), 35\u201344 (2012).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_5_32_2","first-page":"178","article-title":"Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder","volume":"187","author":"Chen HW","year":"2012","unstructured":"Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. Int. Urogynecol. J. 187(1), 178\u2013184 (2012).","journal-title":"Int. Urogynecol. J."},{"issue":"12","key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1592\/phco.26.12.1694","article-title":"Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder","volume":"26","author":"Ko Y","year":"2006","unstructured":"Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 26(12), 1694\u20131702 (2006).","journal-title":"Pharmacotherapy"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0079"},{"key":"e_1_3_5_35_2","first-page":"S157","article-title":"Botox, nerve stimulation devices, mirabegron, and anticholinergics versus best supportive care for overactive bladder: an updated US cost-effectiveness analysis","volume":"40","author":"Murray B","year":"2021","unstructured":"Murray B, Miles-Thomas J, Sussman D Botox, nerve stimulation devices, mirabegron, and anticholinergics versus best supportive care for overactive bladder: an updated US cost-effectiveness analysis. Neurourol. Urodyn. 40, S157\u2013S157 (2021).","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"e_1_3_5_36_2","first-page":"343","article-title":"A pharmacoeconomic model comparing two long-acting treatments for overactive bladder","volume":"8","author":"Noe L","year":"2002","unstructured":"Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J. Manag. Care Pharm. 8(5), 343\u2013352 (2002).","journal-title":"J. Manag. Care Pharm."},{"issue":"4","key":"e_1_3_5_37_2","first-page":"S150","article-title":"Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin","volume":"11","author":"Perfetto EM","year":"2005","unstructured":"Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am. J. Manag. Care 11(Suppl. 4), S150\u2013S157 (2005).","journal-title":"Am. J. Manag. Care"},{"issue":"9","key":"e_1_3_5_38_2","first-page":"1072","article-title":"Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder","volume":"22","author":"Perk S","year":"2016","unstructured":"Perk S, Wielage RC, Campbell NL Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J. Manag. Care Spec. Pharm. 22(9), 1072\u20131084 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3111\/13696998.2015.1111893","article-title":"Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States","volume":"19","author":"Qin L","year":"2016","unstructured":"Qin L, Luo X, Zou KH, Snedecor SJ. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States. J. Med. Econ. 19(3), 229\u2013235 (2016).","journal-title":"J. Med. Econ."},{"issue":"8","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd JP","year":"2018","unstructured":"Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder. Int. Urogynecol. J. 29(8), 1213\u20131219 (2018).","journal-title":"Int. Urogynecol. J."},{"issue":"10","key":"e_1_3_5_41_2","first-page":"S22","article-title":"Cost-effectiveness analysis of mirabegron vs. anticholinergic for initial medical therapy of overactive bladder accounting for risk of dementia","volume":"26","author":"St Martin BS","year":"2020","unstructured":"St Martin BS, Wallace SL, Lee K, Park A, Sokol ER. Cost-effectiveness analysis of mirabegron vs. anticholinergic for initial medical therapy of overactive bladder accounting for risk of dementia. Female Pelvic Med. Reconstr. Surg. 26(10 Suppl. 1), S22\u2013S23 (2020).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"12","key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/13696998.2016.1204307","article-title":"Mirabegron for the treatment of overactive bladder: Cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives","volume":"19","author":"Wielage RC","year":"2016","unstructured":"Wielage RC, Perk S, Campbell NL Mirabegron for the treatment of overactive bladder: Cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J. Med. Econ. 19(12), 1135\u20131143 (2016).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_5_43_2","first-page":"11","article-title":"Comparing direct medical costs of onabotulinumtoxinA with other common overactive bladder interventions","volume":"10","author":"Yehoshua A","year":"2018","unstructured":"Yehoshua A, Murray BP, Vasavada SP, Sand PK. Comparing direct medical costs of onabotulinumtoxinA with other common overactive bladder interventions. Am. J. Pharm. Benefits. 10(1), 11\u201317 (2018).","journal-title":"Am. J. Pharm. Benefits."},{"issue":"3","key":"e_1_3_5_44_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-5347(05)00352-6","article-title":"Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study","volume":"175","author":"Balkrishnan R","year":"2006","unstructured":"Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J. Urol. 175(3 Pt 1), 1067\u20131071; discussion 1071\u20131072 (2006).","journal-title":"J. Urol."},{"key":"e_1_3_5_45_2","first-page":"S139","article-title":"A retrospective study of the prevalence of anticholinergic poly-pharmacy use and its associated outcomes among Medicare patients with overactive bladder","volume":"69","author":"Campbell N","year":"2021","unstructured":"Campbell N, Shiozawa A, Epstein A, Walker D, Lockefeer A, Hines L. A retrospective study of the prevalence of anticholinergic poly-pharmacy use and its associated outcomes among Medicare patients with overactive bladder. J. Am. Geriatr. Soc. 69, S139\u2013S139 (2021).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"8","key":"e_1_3_5_46_2","first-page":"69","article-title":"Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data","volume":"14","author":"Hall JA","year":"2001","unstructured":"Hall JA, Nelson MA, Meyer JW, Williamson T, Wagner S. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag. Care Interface 14(8), 69\u201375 (2001).","journal-title":"Manag. Care Interface"},{"issue":"10","key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3111\/13696998.2014.941066","article-title":"Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder","volume":"17","author":"Ivanova JI","year":"2014","unstructured":"Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. J. Med. Econ. 17(10), 741\u2013750 (2014).","journal-title":"J. Med. Econ."},{"issue":"4","key":"e_1_3_5_48_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00192-013-2246-0","article-title":"Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States","volume":"25","author":"Ju R","year":"2014","unstructured":"Ju R, Garrett J, Wu JM. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int. Urogynecol. J. 25(4), 479\u2013484 (2014).","journal-title":"Int. Urogynecol. J."},{"issue":"23","key":"e_1_3_5_49_2","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2146\/ajhp060038","article-title":"Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin","volume":"63","author":"Jumadilova Z","year":"2006","unstructured":"Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. Am. J. Health Syst. Pharm. 63(23), 2357\u20132364 (2006).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"e_1_3_5_50_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/gps.5467","article-title":"Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder","volume":"36","author":"Kachru N","year":"2021","unstructured":"Kachru N, Holmes HM, Johnson ML, Chen H, Aparasu RR. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int. J. Geriatr. Psychiatry 36(5), 684\u2013696 (2021).","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"e_1_3_5_51_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s41669-020-00215-w","article-title":"Fall\/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder","volume":"5","author":"Lozano-Ortega G","year":"2021","unstructured":"Lozano-Ortega G, Schermer CR, Walker DR Fall\/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon. Open 5(1), 45\u201355 (2021).","journal-title":"Pharmacoecon. Open"},{"issue":"4","key":"e_1_3_5_52_2","first-page":"S130","article-title":"Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates","volume":"11","author":"Nitz NM","year":"2005","unstructured":"Nitz NM, Jumadilova Z, Darkow T, Frytak JR, Bavendam T. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Am. J. Manag. Care. 11(Suppl. 4), S130\u2013S139 (2005).","journal-title":"Am. J. Manag. Care."},{"issue":"4","key":"e_1_3_5_53_2","first-page":"S108","article-title":"Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder","volume":"15","author":"Pelletier EM","year":"2009","unstructured":"Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am. J. Manag. Care. 15(Suppl. 4), S108\u2013S114 (2009).","journal-title":"Am. J. Manag. Care."},{"key":"e_1_3_5_54_2","first-page":"S110","article-title":"Falls or fractures and anticholinergic burden are associated with higher annual all-cause healthcare costs among those with overactive bladder","volume":"38","author":"Rogula B","year":"2019","unstructured":"Rogula B, Lozano-Ortega G, Gooch K Falls or fractures and anticholinergic burden are associated with higher annual all-cause healthcare costs among those with overactive bladder. Neurourol. Urodyn. 38, S110\u2013S110 (2019).","journal-title":"Neurourol. Urodyn."},{"issue":"4","key":"e_1_3_5_55_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jgs.14030","article-title":"Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder","volume":"64","author":"Suehs BT","year":"2016","unstructured":"Suehs BT, Davis C, Franks B Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder. J. Am. Geriatr. Soc. 64(4), 779\u2013787 (2016).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7","key":"e_1_3_5_56_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40266-017-0464-8","article-title":"Impact of 2015 update to the Beers Criteria on estimates of prevalence and costs associated with potentially inappropriate use of antimuscarinics for overactive bladder","volume":"34","author":"Suehs BT","year":"2017","unstructured":"Suehs BT, Davis C, Ng DB, Gooch K. Impact of 2015 update to the Beers Criteria on estimates of prevalence and costs associated with potentially inappropriate use of antimuscarinics for overactive bladder. Drugs Aging 34(7), 535\u2013543 (2017).","journal-title":"Drugs Aging"},{"issue":"3","key":"e_1_3_5_57_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bju.12505","article-title":"Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder","volume":"113","author":"Tang DH","year":"2014","unstructured":"Tang DH, Colayco DC, Khalaf KM Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int. 113(3), 484\u2013491 (2014a).","journal-title":"BJU Int."},{"key":"e_1_3_5_58_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2377-14-74","article-title":"Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity","volume":"14","author":"Tang DH","year":"2014","unstructured":"Tang DH, Colayco D, Piercy J, Patel V, Globe D, Chancellor MB. Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity. BMC Neurol. 14, 74 (2014b).","journal-title":"BMC Neurol."},{"issue":"4","key":"e_1_3_5_59_2","first-page":"S140","article-title":"Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder","volume":"11","author":"Varadharajan S","year":"2005","unstructured":"Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am. J. Manag. Care. 11(Suppl. 4), S140\u2013S149 (2005).","journal-title":"Am. J. Manag. Care."},{"key":"e_1_3_5_60_2","first-page":"S140","article-title":"Cost and resource utilization in frail patients with overactive bladder treated with mirabegron or an antimuscarinic","volume":"69","author":"Walker D","year":"2021","unstructured":"Walker D, Johnson T, Kimura T Cost and resource utilization in frail patients with overactive bladder treated with mirabegron or an antimuscarinic. J. Am. Geriatr. Soc. 69, S140\u2013S140 (2021).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"e_1_3_5_61_2","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","author":"Yehoshua A","year":"2016","unstructured":"Yehoshua A, Chancellor M, Vasavada S Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J. Manag. Care Spec. Pharm. 22(4), 406\u2013413 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"6","key":"e_1_3_5_62_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1185\/03007990802081766","article-title":"Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER","volume":"24","author":"Zinner N","year":"2008","unstructured":"Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr. Med. Res. Opin. 24(6), 1583\u20131591 (2008).","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"e_1_3_5_63_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjopharm.2009.11.004","article-title":"Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis","volume":"7","author":"Zinner N","year":"2009","unstructured":"Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Am. J. Geriatr. Pharmacother. 7(6), 373\u2013382 (2009).","journal-title":"Am. J. Geriatr. Pharmacother."},{"issue":"11","key":"e_1_3_5_64_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40266-020-00792-9","article-title":"Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis","volume":"37","author":"Lozano-Ortega G","year":"2020","unstructured":"Lozano-Ortega G, Walker DR, Johnston K Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis. Drugs Aging 37(11), 801\u2013816 (2020).","journal-title":"Drugs Aging"},{"issue":"5","key":"e_1_3_5_65_2","doi-asserted-by":"crossref","first-page":"e026391","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo SM","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open 9(5), e026391 (2019).","journal-title":"BMJ Open"},{"issue":"1","key":"e_1_3_5_66_2","first-page":"S142","article-title":"The 2012 update to the anticholinergic cognitive burden scale","volume":"61","author":"Campbell N","year":"2013","unstructured":"Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J. Am. Geriatr. Soc. 61(S1), S142\u2013S143 (2013).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7","key":"e_1_3_5_67_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim DH","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J. Gerontol. A Biol. Sci. Med. Sci. 73(7), 980\u2013987 (2018).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"11","key":"e_1_3_5_68_2","doi-asserted-by":"crossref","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell G","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 8(11), e021889 (2018).","journal-title":"BMJ Open"},{"issue":"3","key":"e_1_3_5_69_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","author":"Alzheimer's Association","year":"2019","unstructured":"Alzheimer's Association. 2019 Alzheimer's disease facts and figures. Alzheimers Dement. 15(3), 321\u2013387 (2019).","journal-title":"Alzheimers Dement."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2022-0160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T14:57:44Z","timestamp":1676645864000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":68,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2217\/cer-2022-0160"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0160","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}